These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 28367758)
21. Recurrent Proliferative Glomerulonephritis With Monoclonal IgG Deposits After a Renal Transplant Which Was Insensitive to Pulse Therapy Remitted by Double Filtration Plasmapheresis. Wu D; Chen JS; Cheng DR; Chen H; Li X; Ji SM; Xie KN; Ni XF; Liu ZH; Wen JQ Exp Clin Transplant; 2015 Oct; 13(5):467-70. PubMed ID: 25275829 [TBL] [Abstract][Full Text] [Related]
22. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416 [TBL] [Abstract][Full Text] [Related]
23. Rituximab for recurrent IgA nephropathy in kidney transplantation: A report of three cases and proposed mechanisms. Chancharoenthana W; Townamchai N; Leelahavanichkul A; Wattanatorn S; Kanjanabuch T; Avihingsanon Y; Praditpornsilpa K; Eiam-Ong S Nephrology (Carlton); 2017 Jan; 22(1):65-71. PubMed ID: 26758857 [TBL] [Abstract][Full Text] [Related]
24. Anti-CD20 monoclonal antibody (rituximab) for the treatment of membranous nephropathy after living-unrelated kidney transplantation: a case report. Sirimongkolrat T; Premasathian N; Vongwiwatana A; Limsrichamrern S; Cheunsuchon B; Vasuvattakul S Transplant Proc; 2008 Sep; 40(7):2440-1. PubMed ID: 18790261 [TBL] [Abstract][Full Text] [Related]
25. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor. Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661 [TBL] [Abstract][Full Text] [Related]
26. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up. Zhou XJ; Zhou FD; Wang SX; Zhao MH Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035 [TBL] [Abstract][Full Text] [Related]
27. A case of living-related renal transplant from the donor with membranous nephropathy. Akioka K; Okamoto M; Ushigome H; Nobori S; Suzuki T; Sakai K; Sakamoto S; Urasaki K; Yanagisawa A; Fukatsu A; Yoshimura N Clin Transplant; 2009 Aug; 23 Suppl 20():62-6. PubMed ID: 19594600 [TBL] [Abstract][Full Text] [Related]
28. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation. Anjum N; Nabi Z J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554 [TBL] [Abstract][Full Text] [Related]
29. De novo proliferative glomerulonephritis with monoclonal IgG deposits of the IgG1κ subtype in a kidney allograft. Tsuji T; Miura M; Yanai M; Itami H; Ishii Y; Akimoto M; Fukasawa Y Nephrology (Carlton); 2016 Jul; 21 Suppl 1():44-7. PubMed ID: 26976360 [TBL] [Abstract][Full Text] [Related]
31. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Rosenzwajg M; Languille E; Debiec H; Hygino J; Dahan K; Simon T; Klatzmann D; Ronco P Kidney Int; 2017 Jul; 92(1):227-237. PubMed ID: 28318628 [TBL] [Abstract][Full Text] [Related]
32. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438 [No Abstract] [Full Text] [Related]
33. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390 [TBL] [Abstract][Full Text] [Related]
34. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Müller-Deile J; Schiffer L; Hiss M; Haller H; Schiffer M Eur J Clin Invest; 2015 Dec; 45(12):1260-9. PubMed ID: 26444294 [TBL] [Abstract][Full Text] [Related]
35. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. Guerry MJ; Vanhille P; Ronco P; Debiec H Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779 [No Abstract] [Full Text] [Related]
36. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab. Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233 [TBL] [Abstract][Full Text] [Related]
37. [Treatment of post-transplant glomerulonephritis]. Sandrini S; Valerio F G Ital Nefrol; 2008; 25 Suppl 44():99-106. PubMed ID: 19048593 [TBL] [Abstract][Full Text] [Related]
38. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series. De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594 [TBL] [Abstract][Full Text] [Related]